CD19 and lymphoma: However, since the CD20-targeting CCR by itself was shown to be non-functional, only minor depletion of non-malignant bystander B cells is expected, while the side effects should be clinically tolerable, especially considering the success of leukemia or lymphoma treatment with CD20- or CD19-targeting CAR T cells (37).